Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
2018-003481-13: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease -The Late Presenter Treatment Optimisation Study (LAPTOP)-

Not yet recruiting
3
440
Europe
Biktarvy, Symtuza, [J05AR], [J05AR22], Film-coated tablet, Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences Inc, Janssen Pharmaceutica NV, Gilead Sciences, Inc.,
Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus), A virus that damages patient's immune system causing the patient difficulty to fight off infections and diseases., Diseases [C] - Virus Diseases [C02]
 
 
BIC-T&T, NCT04653194 / 2019-003208-11: Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed
3
36
Europe
Biktarvy, Symtuza
Chelsea and Westminster NHS Foundation Trust, Imperial College London, Gilead Sciences
Human Immunodeficiency Virus
07/23
07/23
NCT03696160: The Late Presenter Treatment Optimisation Study

Active, not recruiting
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24

Download Options